Head

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
금요일, 3월 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Retrieved on: 
금요일, 3월 29, 2024
MSD, Biochemistry, Daiichi Sankyo, Patient, Knowledge, CMC, Cancer, University, Head, Spacecraft, Senior, Research and development, Drug development, Molecular biology, ANL, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.

Key Points: 
  • SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.
  • Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC at CStone Pharmaceuticals, at which he provided strategic leadership and oversight to the research, early clinical development, and CMC aspects of the entire CStone’s pipeline.
  • “We are very pleased to have Dr. Tse join our senior leadership team,” said Carsten Lu, CEO and Chairman of Adlai Nortye.
  • “I'm keen to leveraging my experiences with the outstanding team at Adlai Nortye and unlock the full potential of our pipeline.”

NaaS Technology Inc. Reports Unaudited 2023 Fourth Quarter and Full Year Financial Results

Retrieved on: 
목요일, 3월 28, 2024
Research, EV, PIN, Head, Growth, H.10, RMB, NTR, GTR, Great Wall Motor, Transport, ISG Business School, Translation, Bank statement, Network as a service, Engineering, Energy, Ecosystem, Digital technology, University of Oxford, USD, Marketing, Toyota Group, Economics, Video game

2023 Fourth Quarter Financial Results:

Key Points: 
  • 2023 Fourth Quarter Financial Results:
    Total revenues reached RMB64.4 million (US$9.1 million) for the fourth quarter of 2023, representing an increase of 119% year over year.
  • Total cost of revenues increased 114% from RMB22.3 million for the fourth quarter of 2022 to RMB47.7 million (US$6.7 million) for the fourth quarter of 2023.
  • Total operating expenses increased from RMB128.8 million for the fourth quarter of 2022 to RMB415.5 million (US$58.5 million) for the fourth quarter of 2023.
  • Net margin decreased from negative 431% for the fourth quarter of 2022 to negative 770% for the fourth quarter of 2023 and non-IFRS net margin decreased from negative 380% for the fourth quarter of 2022 to negative 494% for the fourth quarter of 2023.

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

Retrieved on: 
목요일, 3월 28, 2024
Online, Cancer, Research, Lung cancer, IRS, Head, CSC, Tumor microenvironment, Biomarker, Abstract, AACR, Publication, Neoplasm, IGF1R, Drug resistance, Recurrence, STAT3, Escape Room, Neck, Pharmaceutical industry

REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it will present data for its oncology candidate NT219, a first-in-class small molecule, dual-inhibitor of IRS 1/2 and STAT3, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting which takes place April 5-11, 2024, in San Diego, California.

Key Points: 
  • “The growing body of clinical, biomarker, and preclinical data for NT219 demonstrate its potential not only in the lead indication of recurrent/metastatic squamous cell carcinoma of the head and neck, but also in other solid-tumor cancers.
  • These publications at AACR 2024 are a result of the progress made last year both in clinical and preclinical work bringing out NT219’s attributes,” stated Gil Efron, Chief Executive Officer of Purple Biotech.
  • “We look forward to leveraging these data as we move forward with the clinical evaluation of NT219.”
    Dr Hadas Reuveni, VP Research and Development at Purple Biotech, added, “At AACR 2024 we will present new data related to NT219.
  • The presented posters will be available on the Publications section of Purple Biotech’s website, following their presentations at the conference.

Capital Bancorp, Inc. Announces Acquisition of Integrated Financial Holdings, Inc.

Retrieved on: 
목요일, 3월 28, 2024
Capital Bank, USDA, SBA, EVP, Partnership, LLP, Capital, C&I, Head, Acquisition, Small Business Administration, Melissa, CBNK, Government, Security (finance)

At closing, Capital shareholders will own approximately 84% and IFH shareholders will own approximately 16% of the combined company.

Key Points: 
  • At closing, Capital shareholders will own approximately 84% and IFH shareholders will own approximately 16% of the combined company.
  • Including Windsor Advantage’s industry leading government guaranteed servicing platform, Capital is well positioned to capitalize on this growing niche.
  • A. Riddick Skinner, EVP of Government Lending at IFH, will join Capital Bank as Head of Government Guaranteed Lending Program.
  • Raymond James & Associates, Inc. served as financial advisor and Wyrick Robbins Yates & Ponton LLP served as legal advisor to IFH.

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
목요일, 3월 28, 2024
Research, HNC, Symantec Endpoint Protection, Head, Type, Manganese, Chronic kidney disease, Incidence, ASN, CKD, New Drug Application, LAPC, Patient, Layoff, CRL, NDA, Cancer, Galera, Workforce, Pancreatic cancer, Clinical trial, Cisplatin, Society, Therapy, GRECO, File, Food, SOM, FDA, PDUFA, Pharmaceutical industry

We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.

Key Points: 
  • We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.
  • The Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA was August 9, 2023.
  • Research and development expenses were $3.2 million in the fourth quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $2.0 million in the fourth quarter of 2023, compared to $5.0 million for the same period in 2022.

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

Retrieved on: 
목요일, 3월 28, 2024
AbbVie, Inflammation, Growth, AstraZeneca, Astex Pharmaceuticals, Trinity College, Novartis, Patient, Research, Standard of care, University, Head, Trinity College Dublin, Therapy, Cancer, Drug development, Amgen, Marketing, Pharmaceutical industry

Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.

Key Points: 
  • Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
  • Dr. Gallagher has directly led or overseen multiple medical product approvals globally, including biologics and small molecules, across several therapeutic areas.
  • Before joining Syndax Pharmaceuticals in 2023, Dr. Gallagher was Head of Development and Chief Medical Officer of AbbVie.
  • Dr. Gallagher was also appointed to serve as a member of the research and development committee of the board of directors.

GCM Grosvenor Expands Credit Team with Two New Hires

Retrieved on: 
목요일, 3월 28, 2024
RMBS, CLO, Structuring, Knowledge, Blue, Head, Risk assessment, Investment, CDO, GCM, GCMG, GCM Grosvenor, The Carlyle Group, Financial services

These strategic hires underscore GCM Grosvenor's commitment to providing world class credit investment solutions.

Key Points: 
  • These strategic hires underscore GCM Grosvenor's commitment to providing world class credit investment solutions.
  • GCM Grosvenor's credit team leverages its extensive expertise to invest across the entire credit liquidity spectrum in direct, fund, co-investment and secondary investments.
  • Before joining GCM Grosvenor, Ingles held senior positions at The Carlyle Group and PointState Capital, where he managed credit portfolios across various sectors.
  • "GCM Grosvenor is delighted to welcome Brandon Cahill and Scott Ingles to our credit team," said Fred Pollock, Chief Investment Officer of GCM Grosvenor.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
수요일, 3월 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results

Retrieved on: 
수요일, 3월 27, 2024
Principal, PDSB, NCI, Head, Survival, Associate, Incidence, Patient, National Cancer Institute, Cancer, Doctor of Philosophy, Biotechnology, Overalls, Oncology, Neck, ICI, Clinical trial, Immune system, IL-12, ICIS, FDA, Physician, PDS, Food, Pharmaceutical industry

This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.

Key Points: 
  • This decision enables PDS Biotech to focus its resources on the drug regimen it believes has the highest potential to benefit patients with HNSCC and to drive shareholder value.
  • “We have had several discussions with key opinion leaders in HNSCC regarding the use of the triple combination in HNSCC.
  • The NCI clinical trial data show significant promise in the use of PDS01ADC in combination with Versamune® HPV,” said Katharine A.
  • The event will be archived on the Investor Relations section of PDS Biotech’s website for six months.